Amneal Pharmaceuticals, Inc. (AMRX)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$20.35+0.25%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $7.1B
- P/E (trailing)
- 41.5
- Forward P/E
- 17.1
- 52-week range
- $9.56 – $21.18
- 52-week change
- +92.42%
- EPS (trailing)
- $0.49
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $3.0B (+8.05%)
- Net income
- $72.1M
- Operating margin
- 13.1%
- Diluted EPS
- $0.22
- Free cash flow
- $270M
From the company’s annual report on SEC EDGAR.
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease.
Headquarters: Bridgewater, United States · 8,700 employees · amneal.com